Symbols / ELOX $11.75 -3.77% Eloxx Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NCM
ELOX Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Sumit Aggarwal M.B.A.
Exch · Country NCM · United States
Market Cap 40.38M
Enterprise Value 14.16M
Income -8.04M
Sales —
FCF (ttm) —
Book/sh -16.45
Cash/sh 9.24
Employees 10
Insider 10d —
IPO Jun 09, 2026
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -16.55
PEG 1.85
P/S —
P/B -0.71
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 0.40
Current Ratio 0.53
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.32
EPS next Y -0.71
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2023-11-13
Earnings (prior) 2023-11-13
ROA —
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 3.44M
Shs Float 532.09K
Insider Own 0.93%
Instit Own 0.83%
Short Float 1.33%
Short Ratio 1.22
Short Interest 3.25K
52W High 17.50
vs 52W High -32.86%
52W Low 8.20
vs 52W Low 43.29%
Beta -168,027.67
Impl. Vol. —
Rel Volume 0.13
Avg Volume 68.71K
Volume 9.14K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $12.21
Price $11.75
Change -3.77%
About

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$11.75
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
Current target
$11.75
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-07-11 main Oppenheimer Outperform → Outperform $55
2023-04-06 reit Oppenheimer — → Outperform $50
News
RSS: Latest ELOX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-27 AGGARWAL SUMIT Chief Executive Officer — 472,826 $0.00 $39,162
2026-01-23 WALTS ALAN EDMUND PH.D. Director — 1,875 — —
2026-01-23 RUBIN STEVEN DANIEL Director — 1,875 — —
2025-09-19 AGGARWAL SUMIT Chief Executive Officer — 1,000,000 — —
2025-01-24 AGGARWAL SUMIT Director — 30,000 — —
2025-01-24 WALTS ALAN EDMUND PH.D. Director — 3,750 — —
2025-01-24 ANDROSKI LINDSAY J.D. Director — 3,750 — —
2025-01-24 RUBIN STEVEN DANIEL Director — 3,750 — —
2024-10-16 AGGARWAL SUMIT Chief Executive Officer — 165,000 — —
2024-10-16 WALTS ALAN EDMUND PH.D. Director — 12,000 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
-100.00%
6.36
0.00
0.00
Operating Revenue
0.00
-100.00%
6.36
0.00
0.00
Operating Expense
6.44
-27.06%
8.83
-48.94%
17.29
-49.77%
34.42
Research And Development
3.06
-14.57%
3.58
-58.40%
8.60
-63.76%
23.73
Selling General And Administration
3.38
-35.58%
5.25
-39.59%
8.69
-18.72%
10.69
General And Administrative Expense
3.38
-35.58%
5.25
-39.59%
8.69
-18.72%
10.69
Other Gand A
3.38
-35.58%
5.25
-39.59%
8.69
-18.72%
10.69
Total Expenses
6.44
-27.06%
8.83
-48.94%
17.29
-49.77%
34.42
Operating Income
-6.44
-160.86%
-2.47
+85.72%
-17.29
+49.77%
-34.42
EBITDA
-4.95
-169.54%
-1.83
+87.84%
-15.09
+54.84%
-33.42
Normalized EBITDA
-6.28
-182.28%
-2.22
+86.51%
-16.49
+50.59%
-33.37
Reconciled Depreciation
0.00
-100.00%
0.16
-79.73%
0.81
+16.40%
0.69
EBIT
-4.95
-147.42%
-2.00
+87.43%
-15.90
+53.39%
-34.12
Total Unusual Items
1.33
+242.42%
0.39
-72.11%
1.40
+3006.25%
-0.05
Total Unusual Items Excluding Goodwill
1.33
+242.42%
0.39
-72.11%
1.40
+3006.25%
-0.05
Special Income Charges
1.24
+9415.38%
0.01
+108.78%
-0.15
0.00
Other Special Charges
-1.24
-5044.00%
0.03
-94.27%
0.44
—
Restructuring And Mergern Acquisition
—
—
—
—
Net Income
-6.00
-90.74%
-3.14
+81.57%
-17.05
+52.71%
-36.06
Pretax Income
-6.00
-90.74%
-3.14
+81.57%
-17.05
+52.71%
-36.06
Net Non Operating Interest Income Expense
-0.86
+22.83%
-1.12
-24.25%
-0.90
+46.33%
-1.68
Interest Expense Non Operating
1.05
-8.30%
1.14
-0.61%
1.15
-40.94%
1.95
Net Interest Income
-0.86
+22.83%
-1.12
-24.25%
-0.90
+46.33%
-1.68
Interest Expense
1.05
-8.30%
1.14
-0.61%
1.15
-40.94%
1.95
Interest Income Non Operating
0.03
+22.22%
0.03
-89.29%
0.25
-8.03%
0.27
Interest Income
0.03
+22.22%
0.03
-89.29%
0.25
-8.03%
0.27
Other Income Expense
1.30
+195.25%
0.44
-60.99%
1.13
+3806.90%
0.03
Other Non Operating Income Expenses
-0.03
-150.94%
0.05
+120.23%
-0.26
-440.26%
0.08
Gain On Sale Of Security
0.10
-74.73%
0.38
-75.63%
1.54
+3314.58%
-0.05
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-6.00
-90.74%
-3.14
+81.57%
-17.05
+52.71%
-36.06
Net Income From Continuing Operation Net Minority Interest
-6.00
-90.74%
-3.14
+81.57%
-17.05
+52.71%
-36.06
Net Income From Continuing And Discontinued Operation
-6.00
-90.74%
-3.14
+81.57%
-17.05
+52.71%
-36.06
Net Income Continuous Operations
-6.00
-90.74%
-3.14
+81.57%
-17.05
+52.71%
-36.06
Normalized Income
-7.33
-107.45%
-3.53
+80.86%
-18.45
+48.78%
-36.02
Net Income Common Stockholders
-6.00
-90.74%
-3.14
+81.57%
-17.05
+52.71%
-36.06
Diluted EPS
-5.39
+41.67%
-9.24
+87.33%
-72.93
+60.18%
-183.15
Basic EPS
-5.39
+41.67%
-9.24
+87.33%
-72.93
+60.18%
-183.15
Basic Average Shares
1.12
+228.50%
0.34
+46.22%
0.23
+18.66%
0.20
Diluted Average Shares
1.12
+228.50%
0.34
+46.22%
0.23
+18.66%
0.20
Diluted NI Availto Com Stockholders
-6.00
-90.74%
-3.14
+81.57%
-17.05
+52.71%
-36.06
Gain On Sale Of PPE
0.00
-97.37%
0.04
-86.81%
0.29
—
Total Other Finance Cost
-0.15
—
—
—
Line Item Trend 2022-12-31 2021-12-31
Total Assets
21.12
—
Current Assets
20.13
—
Cash Cash Equivalents And Short Term Investments
19.21
—
Cash And Cash Equivalents
19.21
—
Receivables
—
—
Accounts Receivable
—
—
Other Receivables
—
—
Prepaid Assets
0.09
-24.39%
0.12
Restricted Cash
0.26
—
Other Current Assets
0.57
—
Total Non Current Assets
0.99
—
Net PPE
0.99
—
Gross PPE
1.17
—
Accumulated Depreciation
-0.18
—
Properties
0.00
—
Machinery Furniture Equipment
0.04
—
Construction In Progress
0.00
-100.00%
0.02
Other Properties
1.08
-35.34%
1.66
Leases
0.06
—
Total Liabilities Net Minority Interest
31.78
—
Current Liabilities
23.09
—
Payables And Accrued Expenses
5.82
—
Payables
3.02
—
Accounts Payable
3.02
—
Current Accrued Expenses
2.80
—
Current Debt And Capital Lease Obligation
4.69
—
Current Debt
3.98
—
Other Current Borrowings
3.98
—
Current Capital Lease Obligation
0.71
—
Current Deferred Liabilities
12.54
—
Current Deferred Revenue
12.54
—
Other Current Liabilities
0.04
-98.79%
3.72
Total Non Current Liabilities Net Minority Interest
8.69
—
Long Term Debt And Capital Lease Obligation
8.69
—
Long Term Debt
8.56
-28.67%
12.00
Long Term Capital Lease Obligation
0.14
—
Stockholders Equity
-10.66
—
Common Stock Equity
-10.66
—
Capital Stock
0.02
—
Common Stock
0.02
—
Preferred Stock
0.00
—
Share Issued
0.20
-0.48%
0.20
Ordinary Shares Number
0.20
+0.01%
0.20
Treasury Shares Number
0.00
-100.00%
0.00
Additional Paid In Capital
263.71
—
Retained Earnings
-274.39
—
Treasury Stock
0.00
-100.00%
2.19
Total Equity Gross Minority Interest
-10.66
—
Total Capitalization
-2.10
—
Working Capital
-2.96
—
Invested Capital
1.88
—
Total Debt
13.38
—
Net Debt
—
—
Capital Lease Obligations
0.85
—
Net Tangible Assets
-10.66
—
Tangible Book Value
-10.66
—
Dueto Related Parties Current
—
3.72
Interest Payable
0.15
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-6.33
-34.19%
-4.71
+67.12%
-14.34
+54.97%
-31.84
Cash Flow From Continuing Operating Activities
-6.33
-34.19%
-4.71
+67.12%
-14.34
+54.97%
-31.84
Net Income From Continuing Operations
-6.00
-90.74%
-3.14
+81.57%
-17.05
+52.71%
-36.06
Depreciation Amortization Depletion
0.00
-100.00%
0.16
-79.73%
0.81
+16.40%
0.69
Depreciation
0.00
-100.00%
0.16
-79.73%
0.81
+16.40%
0.69
Depreciation And Amortization
0.00
-100.00%
0.16
-79.73%
0.81
+16.40%
0.69
Other Non Cash Items
0.24
-47.65%
0.47
-4.49%
0.49
-9.43%
0.54
Stock Based Compensation
0.23
-56.56%
0.54
-72.47%
1.97
-34.96%
3.02
Asset Impairment Charge
—
—
—
0.04
Operating Gains Losses
-1.33
-242.42%
-0.39
+72.11%
-1.40
-3200.00%
0.04
Gain Loss On Investment Securities
-0.10
+74.73%
-0.38
+75.63%
-1.54
-3528.89%
0.04
Gain Loss On Sale Of PPE
-0.00
+97.37%
-0.04
+86.81%
-0.29
0.00
Change In Working Capital
0.52
+122.07%
-2.36
-379.15%
0.84
+815.25%
-0.12
Change In Receivables
2.36
+200.00%
-2.36
0.00
—
Changes In Account Receivables
2.36
+200.00%
-2.36
0.00
—
Change In Prepaid Assets
-0.34
-748.08%
0.05
-88.87%
0.47
+85.32%
0.25
Change In Payables And Accrued Expense
-1.86
-521.09%
0.44
-59.50%
1.09
+346.31%
0.24
Change In Accrued Expense
0.78
-2.27%
0.79
+149.94%
-1.59
-13.82%
-1.40
Change In Payable
-2.63
-645.89%
-0.35
-113.18%
2.68
+63.25%
1.64
Change In Account Payable
-2.63
-645.89%
-0.35
-113.18%
2.68
+63.25%
1.64
Change In Other Working Capital
0.36
+200.00%
-0.36
—
—
Change In Other Current Liabilities
-0.00
+96.95%
-0.13
+81.60%
-0.71
-15.96%
-0.61
Investing Cash Flow
0.00
-97.37%
0.04
-87.70%
0.31
+568.18%
-0.07
Cash Flow From Continuing Investing Activities
0.00
-97.37%
0.04
-87.70%
0.31
+568.18%
-0.07
Net PPE Purchase And Sale
0.00
-97.37%
0.04
-87.70%
0.31
+568.18%
-0.07
Purchase Of PPE
—
—
—
-0.07
Sale Of PPE
0.00
-97.37%
0.04
-87.70%
0.31
—
Capital Expenditure
—
—
—
-0.07
Net Investment Purchase And Sale
—
—
—
—
Purchase Of Investment
—
—
—
—
Sale Of Investment
—
—
—
—
Net Business Purchase And Sale
—
—
—
0.00
Financing Cash Flow
11.00
+219.89%
3.44
+184.25%
-4.08
-146.32%
8.81
Cash Flow From Continuing Financing Activities
11.00
+219.89%
3.44
+184.25%
-4.08
-146.32%
8.81
Net Issuance Payments Of Debt
1.61
-47.35%
3.06
+132.53%
-9.40
0.00
Issuance Of Debt
2.87
-21.89%
3.67
0.00
0.00
Repayment Of Debt
-1.25
-105.74%
-0.61
+93.51%
-9.40
0.00
Long Term Debt Issuance
2.87
-21.89%
3.67
0.00
0.00
Long Term Debt Payments
-1.25
-105.74%
-0.61
+93.51%
-9.40
0.00
Net Long Term Debt Issuance
1.61
-47.35%
3.06
+132.53%
-9.40
0.00
Net Common Stock Issuance
0.00
0.00
-100.00%
4.89
0.00
Proceeds From Stock Option Exercised
9.69
0.00
0.00
0.00
Net Other Financing Charges
-0.30
-178.74%
0.38
-11.60%
0.43
-95.11%
8.81
Changes In Cash
4.67
+477.63%
-1.24
+93.17%
-18.11
+21.58%
-23.10
Beginning Cash Position
0.12
-91.43%
1.35
-93.04%
19.47
-54.27%
42.57
End Cash Position
4.79
+4030.17%
0.12
-91.43%
1.35
-93.04%
19.47
Free Cash Flow
-6.33
-34.19%
-4.71
+67.12%
-14.34
+55.06%
-31.91
Interest Paid Supplemental Data
0.03
-82.01%
0.14
-85.95%
0.99
-27.55%
1.36
Income Tax Paid Supplemental Data
—
—
—
—
Amortization Of Securities
—
—
—
—
Common Stock Issuance
0.00
0.00
-100.00%
4.89
0.00
Issuance Of Capital Stock
0.00
0.00
-100.00%
4.89
0.00
Sale Of Business
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category